FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
32.72 USD
0 (0%)
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
Operating Cash Flow
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
Cap Ex
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
Free Cash Flow
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
Wacc
9.25
9.25
9.25
9.25
9.25
Pv Lfcf
-1.86M
-1.45M
-1.13M
-881.81k
-687.64k
Sum Pv Lfcf
-6.01M
